Indications of Binimetinib

1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

Binimetinib is indicated, in combination with encorafenib, for the treatment of patients with unresectable or  metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.  

2 BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Binimetinib is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic  non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

from FDA，2024.09